Connect Biopharma Presents Key Findings at ERS Congress 2025
SAN DIEGO — Connect Biopharma Holdings Limited (NASDAQ: CNTB), a leading clinical-stage biopharmaceutical company known for its efforts in treating inflammatory diseases, has announced that it will be presenting two important studies at the upcoming European Respiratory Society (ERS) Congress 2025. This prestigious event is set to take place from September 27 to October 1, with both in-person and virtual attendance options.
Details of the Presentations
The first study to be showcased is titled "Rademikibart in Moderate-to-Severe Asthma: Impact of Eosinophils and Regional Differences on Response." This research will be presented by Raúl Collazo, Ph.D., and is part of the Biologics for Asthma and Allergic Rhinitis session. Attendees can expect to learn more about the anatomical and physiological differences affecting patients' responses to Rademikibart, during the session on Monday, September 29, from 8:00 a.m. to 9:30 a.m. CET.
Exploring Eosinophils' Role
In this presentation, the focus will be on how eosinophils, a type of white blood cell involved in the inflammatory response, influence the effectiveness of treatments for asthma. This could have significant implications for personalized treatment strategies in asthma management.
Second Presentation Highlights
The second poster presentation is equally exciting and titled "Rapid and Sustained FEV1 Improvements with Rademikibart in Type 2 Asthma: Impact of Eosinophils and FENO," also to be delivered by Dr. Raúl Collazo during the same session. This study aims to reveal the benefits of Rademikibart in improving lung function measurements in patients and how eosinophil levels accompany these improvements.
Impact on Patient Outcomes
Connecting the dots between eosinophilic activity and lung function metrics can pave the way for more effective interventions. Such findings potentially represent a leap forward in asthma treatment, underscoring Connect Biopharma’s commitment to enhancing patient care.
About Rademikibart
Rademikibart is a human monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4R?). By inhibiting IL-4 and IL-13 functions, Rademikibart may alter the T helper 2 (Th2) inflammatory responses, a primary driver in conditions like atopic dermatitis and asthma. This innovative approach strives to address the underlying mechanisms of these diseases rather than just alleviating symptoms.
Connect Biopharma's Mission
Connect Biopharma is dedicated to transforming the treatment landscape for asthma and chronic obstructive pulmonary disease (COPD). The Company is focused on advancing research and development efforts surrounding Rademikibart, which is currently undergoing extensive global clinical trials aimed at addressing acute asthma and COPD exacerbations.
Furthermore, Connect Biopharma has partnered with Simcere in China for the development and marketing of Rademikibart, tapping into new markets to disseminate its groundbreaking therapies.
Looking Ahead
The forthcoming presentations at the ERS Congress represent a pivotal moment for Connect Biopharma as it seeks to leave its mark on the biopharmaceutical landscape. Providing new data about Rademikibart could encourage collaboration and interest from industry stakeholders, leading to potential partnerships that may further influence asthma management strategies.
For further information on their clinical programs and ongoing research initiatives, interested parties can visit the official website of Connect Biopharma.
Frequently Asked Questions
What is Connect Biopharma's main focus?
Connect Biopharma is primarily focused on transforming treatments for inflammatory diseases, particularly asthma and COPD.
When will the presentations at the ERS Congress take place?
The presentations are scheduled for Monday, September 29, from 8:00 a.m. to 9:30 a.m. CET.
Who is presenting the studies?
Both presentations will be delivered by Dr. Raúl Collazo, a key researcher at Connect Biopharma.
What is Rademikibart?
Rademikibart is a monoclonal antibody targeting IL-4R?, designed to block inflammatory pathways involved in asthma and similar conditions.
Is Rademikibart approved for marketing yet?
No, Rademikibart is still under clinical investigation and has not yet received regulatory approval.
